Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma

被引：1
|
作者：
Fukumoto, Takeshi [1 ]
Horita, Nobuyuki [2 ]
机构：
[1] Kobe Univ, Grad Sch Med, Dept Internal Related, Div Dermatol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 147卷
关键词：
STAGE IV MELANOMA; DOUBLE-BLIND; IPILIMUMAB; NIVOLUMAB; PLACEBO;
D O I：
10.1016/j.ejca.2021.01.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [31] Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
    van Akkooi, Alexander C. J.
    Zijlker, Lisanne P.
    Wouters, Michel W. J. M.
    BIODRUGS, 2022, 36 (03) : 373 - 380
  • [32] Dual Checkpoint Inhibition for Advanced Melanoma
    不详
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (05) : 1242 - 1242
  • [33] Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
    Lai, Xiulan
    Friedman, Avner
    BMC SYSTEMS BIOLOGY, 2017, 11
  • [34] Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
    Wu, Chiao-En
    Yang, Chan-Keng
    Peng, Meng-Ting
    Huang, Pei-Wei
    Lin, Yu-Fen
    Cheng, Chi-Yuan
    Chang, Yao-Yu
    Chen, Huan-Wu
    Hsieh, Jia-Juan
    Chang, John Wen-Cheng
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [35] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2023, 18 (01) : 159 - 168
  • [36] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2023, 18 : 159 - 168
  • [37] Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor
    Zhou, Qingbo
    Liu, Jianjiang
    Xie, Shaoqin
    MEDICINE, 2024, 103 (22) : E38329
  • [38] Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies
    Harrold, Emily C.
    Keane, Fergus
    Cercek, Andrea
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (04) : 162 - 173
  • [39] The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer
    Cai, Changjing
    Han, Ying
    Peng, Yinghui
    Zhang, Xiangyang
    Gan, Pingping
    Tang, Youhong
    Tang, Lanhua
    Liu, Yiping
    Shen, Hong
    Zeng, Shan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Fibrillary Glomerulonephritis in a Patient on Dual Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Therapy
    Chewcharat, Api
    Chowdhury, Raad Bin Zakir
    Petrosyan, Romela
    Shah, Sujal I.
    Gupta, Shruti
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
12345